Research progress on therapeutic targeting of quiescent cancer cells
Source abstract
Abstract
Cellular quiescence (G0) is a sleep-like cellular state that allows cells to maintain the ability to re-enter and exit the proliferative cycle. Quiescent cancer cells are considered a therapeutic challenge since they are often resistant to conventional chemoradiotherapy resulting in disease progression and relapse. To date, the majority of published studies have focused on identifying molecules that target proliferating tumor cells while limited information is available on methods to target quiescent cancer cells. This review provides a summary of the relevant molecular mechanisms underlying quiescence maintenance and pharmacological interventions aimed at either eliminating this cancer cell subpopulation or indefinitely maintaining the quiescence state. Furthermore, the irradiation responses of quiescent cancer cells, in particular, the influence of manipulating intratumor hypoxia and radiation properties on radiosensitivity, are discussed. The main aim of this article is to provide a theoretical basis for the effective targeted killing of dormant tumor cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiation Medicine, Institute of Modern Physics, Chinese Academy of Sciences
Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences
College of Life Sciences, University of Chinese Academy of Sciences
School of Pharmacy, Lanzhou University
Funding
the Ministry of science and technology national key R & D project · the Key Program of the National Natural Science Foundation of China · the National Natural Science Foundation of China
References (96)
Show source-provided references
1. 10.3390/ijms2009215810.3390/ijms20092158 ↗
2. 10.1007/s00294-018-00928-w10.1007/s00294-018-00928-w ↗
3. 10.1371/journal.pone.013479310.1371/journal.pone.0134793 ↗
4. 10.18632/oncotarget.1683910.18632/oncotarget.16839 ↗
5. 10.1091/mbc.e12-03-019210.1091/mbc.e12-03-0192 ↗
6. 10.18632/oncotarget.527710.18632/oncotarget.5277 ↗
7. 10.18632/oncotarget.1463410.18632/oncotarget.14634 ↗
8. 10.1002/jcb.2576810.1002/jcb.25768 ↗
9. 10.1038/srep0401210.1038/srep04012 ↗
10. 10.1387/ijdb.160343LB10.1387/ijdb.160343LB ↗
11. 10.1259/bjr.2012030210.1259/bjr.20120302 ↗
12. 10.1016/j.trecan.2018.10.01010.1016/j.trecan.2018.10.010 ↗
13. 10.1080/15384101.2016.125903910.1080/15384101.2016.1259039 ↗
14. 10.1259/bjr/5701564210.1259/bjr/57015642 ↗
15. 10.1016/j.stem.2017.10.00110.1016/j.stem.2017.10.001 ↗
16. 10.1155/2018/375354710.1155/2018/3753547 ↗
17. 10.1242/jcs.21302510.1242/jcs.213025 ↗
18. 10.1242/jcs.21733110.1242/jcs.217331 ↗
19. 10.1016/j.isci.2018.06.01110.1016/j.isci.2018.06.011 ↗
20. 10.1091/mbc.E19-04-019010.1091/mbc.E19-04-0190 ↗
21. 10.1186/s13059-015-0766-210.1186/s13059-015-0766-2 ↗
22. 10.1534/genetics.115.18150310.1534/genetics.115.181503 ↗
23. 10.1126/sciadv.aat568510.1126/sciadv.aat5685 ↗
24. 10.1111/gtc.1266510.1111/gtc.12665 ↗
25. 10.1074/jbc.M115.70008810.1074/jbc.M115.700088 ↗
26. 10.1371/journal.pone.013003210.1371/journal.pone.0130032 ↗
27. 10.1016/j.celrep.2017.04.05510.1016/j.celrep.2017.04.055 ↗
28. 10.1371/journal.pone.006509710.1371/journal.pone.0065097 ↗
29. 10.1073/pnas.161229011310.1073/pnas.1612290113 ↗
30. 10.1371/journal.pone.007854510.1371/journal.pone.0078545 ↗
31. 10.1016/j.tips.2018.12.00410.1016/j.tips.2018.12.004 ↗
32. 10.1038/ncomms717010.1038/ncomms7170 ↗
33. 10.4161/cc.2910410.4161/cc.29104 ↗
34. 10.1111/febs.1434710.1111/febs.14347 ↗
35. 10.4161/cc.8.1.750710.4161/cc.8.1.7507 ↗
36. 10.1093/nar/gkv56710.1093/nar/gkv567 ↗
37. 10.1016/j.cell.2013.08.06210.1016/j.cell.2013.08.062 ↗
38. 10.1016/j.freeradbiomed.2012.06.01910.1016/j.freeradbiomed.2012.06.019 ↗
39. 10.1126/science.aao422710.1126/science.aao4227 ↗
40. 10.1038/s41586-018-0387-510.1038/s41586-018-0387-5 ↗
41. 10.1016/j.synbio.2018.10.00610.1016/j.synbio.2018.10.006 ↗
42. 10.1074/jbc.M80728220010.1074/jbc.M807282200 ↗
43. 10.1096/fj.15-27841610.1096/fj.15-278416 ↗
44. 10.1080/15384047.2019.157996110.1080/15384047.2019.1579961 ↗
45. 10.1038/nrc391010.1038/nrc3910 ↗
46. 10.1016/j.critrevonc.2013.12.00910.1016/j.critrevonc.2013.12.009 ↗
47. 10.1172/JCI7025910.1172/JCI70259 ↗
48. 10.1084/jem.2017138510.1084/jem.20171385 ↗
49. 10.1038/aps.2016.3410.1038/aps.2016.34 ↗
50. 10.1016/j.ejphar.2014.11.04010.1016/j.ejphar.2014.11.040 ↗
51. 10.15698/mic2018.02.61510.15698/mic2018.02.615 ↗
52. 10.1080/23723556.2017.140353110.1080/23723556.2017.1403531 ↗
53. 10.1158/0008-5472.CAN-13-057910.1158/0008-5472.CAN-13-0579 ↗
54. 10.1158/0008-5472.CAN-11-305910.1158/0008-5472.CAN-11-3059 ↗
55. 10.1158/0008-5472.CAN-15-337710.1158/0008-5472.CAN-15-3377 ↗
56. 10.1074/jbc.M112.39029410.1074/jbc.M112.390294 ↗
57. 10.3892/or.2015.416910.3892/or.2015.4169 ↗
58. 10.1517/14728222.2013.81572810.1517/14728222.2013.815728 ↗
59. 10.1091/mbc.e17-03-016210.1091/mbc.e17-03-0162 ↗
60. 10.1083/jcb.20071115410.1083/jcb.200711154 ↗
61. 10.18632/oncotarget.2122110.18632/oncotarget.21221 ↗
62. 10.1186/s12885-015-1460-110.1186/s12885-015-1460-1 ↗
63. 10.1158/0008-5472.CAN-08-385810.1158/0008-5472.CAN-08-3858 ↗
64. 10.1182/blood-2010-04-27885310.1182/blood-2010-04-278853 ↗
65. 10.18632/oncotarget.2287110.18632/oncotarget.22871 ↗
66. 10.1016/j.bbamcr.2017.01.01010.1016/j.bbamcr.2017.01.010 ↗
67. 10.18632/oncotarget.2550910.18632/oncotarget.25509 ↗
68. 10.1038/nature1361110.1038/nature13611 ↗
69. 10.1016/j.trecan.2016.10.00910.1016/j.trecan.2016.10.009 ↗
70. 10.1038/ncomms429510.1038/ncomms4295 ↗
71. 10.1038/s41598-018-36608-510.1038/s41598-018-36608-5 ↗
72. 10.1038/d41586-018-05445-x10.1038/d41586-018-05445-x ↗
73. 10.1016/j.celrep.2017.02.01310.1016/j.celrep.2017.02.013 ↗
74. 10.1038/srep3647810.1038/srep36478 ↗
75. 10.1016/j.bbrc.2015.01.07610.1016/j.bbrc.2015.01.076 ↗
76. 10.2147/HP.S9341310.2147/HP.S93413 ↗
77. 10.1093/glycob/cwu06210.1093/glycob/cwu062 ↗
78. 10.1158/1541-7786.MCR-14-0153-T10.1158/1541-7786.MCR-14-0153-T ↗
79. 10.1371/journal.pone.014736610.1371/journal.pone.0147366 ↗
80. 10.3892/etm.2014.170410.3892/etm.2014.1704 ↗
81. Masunaga SI, Sanada Y, Moriwaki T, et al. Significance of fractionated administration of thalidomide combined with γ-ray irradiation in terms of local tumor response and lung metastasis. World J Oncol. 2014;5:155–165.
82. 10.1007/s11604-009-0397-110.1007/s11604-009-0397-1 ↗
83. 10.1259/bjr/3845793810.1259/bjr/38457938 ↗
84. 10.1007/s00432-009-0552-110.1007/s00432-009-0552-1 ↗
85. 10.14740/wjon1058w10.14740/wjon1058w ↗
86. 10.1093/jrr/rrs09410.1093/jrr/rrs094 ↗
87. Masunaga SI, Liu Y, Tanaka H, et al. Radiosensitivity and capacity to recover from radiation-induced damage in pimonidazole-unlabeled intratumor quiescent cells depend on p53 status. World J Oncol. 2011;2:1–9.
88. 10.1667/RR13726.110.1667/RR13726.1 ↗
89. 10.1080/15384101.2018.148021710.1080/15384101.2018.1480217 ↗
90. 10.1016/j.lungcan.2008.12.02610.1016/j.lungcan.2008.12.026 ↗
91. 10.1016/j.pan.2018.08.00710.1016/j.pan.2018.08.007 ↗
92. 10.1016/j.apradiso.2015.08.01910.1016/j.apradiso.2015.08.019 ↗
93. 10.1016/j.jphs.2019.01.01210.1016/j.jphs.2019.01.012 ↗
94. 10.1186/1748-717X-8-19510.1186/1748-717X-8-195 ↗
95. 10.1093/jrr/rrx08010.1093/jrr/rrx080 ↗
96. 10.1259/bjr/2097489910.1259/bjr/20974899 ↗